PURPOSE: To determine the unique contribution of vision-specific distress in predicting depressive symptoms in people with vision impairment attending a tertiary eye care clinic. METHODS: In this cross-sectional study, interview-administered surveys were conducted with 143 adult patients who had presenting visual acuity <0.3 logMAR. Depressive symptoms were assessed with the Patient Health Questionnaire-9 and vision-specific distress was assessed with the Impact of Vision Impairment (IVI) Questionnaire emotional well-being subscale. In addition, level of restriction of participation in common daily activities due to vision impairment was assessed with the IVI and measures of general physical health and social support were included. RESULTS: Twenty-one (14.7%) of 143 participants reported clinically significant depressive symptoms and an additional 27.3% (n = 39) had mild depressive symptoms. Vision-specific distress was the strongest unique predictor of depressive symptoms (beta = 0.37, P < 0.001), with physical health (beta = -0.22, P < 0.01), age (beta = -0.18, P < 0.05), and experience of a negative life event (beta = 0.15, P < 0.05) also contributing significantly to depressive symptoms. Results also indicated that vision-specific distress mediates the impact of participation restriction due to vision impairment on depressive symptoms. CONCLUSIONS: An assessment of vision-specific distress may be a useful tool with which to identify those at risk of depression or in need of early intervention in eye care or rehabilitation settings. Depression treatment approaches or depression prevention strategies for people with vision impairment may benefit from a focus on vision-specific distress.
PURPOSE: To determine the unique contribution of vision-specific distress in predicting depressive symptoms in people with vision impairment attending a tertiary eye care clinic. METHODS: In this cross-sectional study, interview-administered surveys were conducted with 143 adult patients who had presenting visual acuity <0.3 logMAR. Depressive symptoms were assessed with the Patient Health Questionnaire-9 and vision-specific distress was assessed with the Impact of Vision Impairment (IVI) Questionnaire emotional well-being subscale. In addition, level of restriction of participation in common daily activities due to vision impairment was assessed with the IVI and measures of general physical health and social support were included. RESULTS: Twenty-one (14.7%) of 143 participants reported clinically significant depressive symptoms and an additional 27.3% (n = 39) had mild depressive symptoms. Vision-specific distress was the strongest unique predictor of depressive symptoms (beta = 0.37, P < 0.001), with physical health (beta = -0.22, P < 0.01), age (beta = -0.18, P < 0.05), and experience of a negative life event (beta = 0.15, P < 0.05) also contributing significantly to depressive symptoms. Results also indicated that vision-specific distress mediates the impact of participation restriction due to vision impairment on depressive symptoms. CONCLUSIONS: An assessment of vision-specific distress may be a useful tool with which to identify those at risk of depression or in need of early intervention in eye care or rehabilitation settings. Depression treatment approaches or depression prevention strategies for people with vision impairment may benefit from a focus on vision-specific distress.
Authors: Eva K Fenwick; Bao Sheng Loe; Jyoti Khadka; Ryan E K Man; Gwyn Rees; Ecosse L Lamoureux Journal: Qual Life Res Date: 2019-11-09 Impact factor: 4.147
Authors: Eva K Fenwick; Peng Guan Ong; Charumathi Sabanayagam; Gwyn Rees; Jing Xie; Edith Holloway; Ching-Yu Cheng; Tien Y Wong; Blanche Lim; Pok Chien Tan; Ecosse L Lamoureux Journal: Qual Life Res Date: 2015-09-29 Impact factor: 4.147
Authors: Judith E Goldstein; Robert W Massof; James T Deremeik; Sonya Braudway; Mary Lou Jackson; K Bradley Kehler; Susan A Primo; Janet S Sunness Journal: Arch Ophthalmol Date: 2012-08
Authors: Xinzhi Zhang; Kai McKeever Bullard; Mary Frances Cotch; M Roy Wilson; Barry W Rovner; Gerald McGwin; Cynthia Owsley; Lawrence Barker; John E Crews; Jinan B Saaddine Journal: JAMA Ophthalmol Date: 2013-05 Impact factor: 7.389